GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Therapeutics Corp (NAS:UTHR) » Definitions » Net Change in Cash

UTHR (United Therapeutics) Net Change in Cash : $490 Mil (TTM As of Dec. 2024)


View and export this data going back to 1999. Start your Free Trial

What is United Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

United Therapeutics's Net Change in Cash for the three months ended in Dec. 2024 was $143 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was $490 Mil.

United Therapeutics Net Change in Cash Historical Data

The historical data trend for United Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Net Change in Cash Chart

United Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 156.10 66.40 246.50 489.50

United Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.00 43.80 104.20 198.20 143.30

United Therapeutics Net Change in Cash Calculation

United Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=1327.1+417.2+-1254.8+0
=490

United Therapeutics's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=341.2+-123.2+-74.7+0
=143

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $490 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

United Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Therapeutics Corp (NAS:UTHR) » Definitions » Net Change in Cash
Comparable Companies
ITCI NBIX VTRS LNTH ALKS ELAN PBH PRGO ALVO AMRX ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
UTH:Germany UTH:Germany U2TH34:Brazil
Address
1000 Spring Street, Silver Spring, MD, USA, 20910
Website
https://www.unither.com
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Executives
Paul A Mahon officer: EVP & General Counsel
Raymond Dwek director
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Christopher Patusky director
Michael Benkowitz officer: President and COO C/O UNITED THERAPEUTICS CORP, 1040 SPRING STREET, SILVER SPRING MD 20910
Ray Kurzweil director
Nilda Mesa director C/O UNITED THERAPEUTICS CORPORATION, 1040 SPRING STREET, SILVER SPRING MD 20910
Louis W Sullivan director
Judy D. Olian director 2000 AVENUE OF THE STARS 12TH FL, LOS ANGELES CA 90067
Richard Giltner director C/O UNITED THERAPEUTICS CORPORTION, 1735 CONNECTICUT AVE. NW, WASHINGTON DC 20009
James Edgemond officer: CFO and Treasurer 1040 SPRING STREET, SILVER SPRING MD 20910
Christopher Causey director
Martine A Rothblatt director, officer: Chief Executive Officer
Linda Maxwell director 1040 SPRING STREET, SILVER SPRING NC 27709
Katherine J Klein director STEINBERG HALL-DIETRICH HALL, 3620 LOCUST WALK, PHILADELPHIA PA 19104